CHF-6366

• Description :

  CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM) . CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) [1].

• UNSPSC :

  12352005

• Target :

  Adrenergic Receptor; Calcium Channel; mAChR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Endocrinology; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/chf-6366.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=NN(C)C(COC2=CC=CC([C@H](C3=CC=CC=C3)NC(O[C@H]4CN5CCC4CC5)=O)=C2)=C1)OCCCCNC[C@H](O)C6=CC=C(O)C7=C6C=CC(N7)=O

• Molecular Formula :

  C42H48N6O8

• Molecular Weight :

  764.87

• References & Citations :

  [1]Carzaniga L, et al. Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases. J Med Chem. 2022 Aug 11;65 (15) :10233-10250.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  MAChR3

• CAS Number :

  [1615208-41-7]